The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
JB Chemicals will pay Rs 125 crore to Novartis to license the same drug portfolio for the Indian market
Submissions based on positive data from the Phase 3 BASIS trial, which were presented this past weekend at the American Society of Hematology (ASH) Annual Meeting
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
The CAPSUL solution enables optimal process performance for production of premier quality PCL grades at competitive rates
The product has been in-licensed from Strides and will be commercialized by Amneal
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
The companies plan to start a pivotal Phase 3 trial in the coming months
Subscribe To Our Newsletter & Stay Updated
